GlassScriptPhysician profile
Mahakit Inklab
NPI 1124229869
$6,226.18
in general payments reported to CMS, 2019-2025
52 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $121 · 2021: $1,524 · 2022: $664 · 2023: $562 · 2024: $1,195 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.95 |
| Education | $212.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $518.07 | 2019-2025 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $491.59 | 2021-2025 | |
| Janssen Biotech, INC. | $392.92 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $380.36 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $318.14 | 2021-2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $304.75 | 2019-2025 | Imfinzi, Enhertu |
| Amgen INC. | $274.83 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $227.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $208.23 | 2021-2025 | Ojjaara |
| Beone Medicines USA, INC. | $205.45 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $192.06 | 2020-2025 | Injectafer, Enhertu |
| Celgene Corporation | $191.64 | 2021-2025 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.22 | 2020-2024 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $189.24 | 2022-2025 | Fotivda |
| Seagen INC. | $156.37 | 2021-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $132.43 | 2019-2025 | |
| Exelixis INC. | $123.07 | 2021-2025 | Cabometyx |
| Beigene USA, INC. | $120.19 | 2021-2025 | Brukinsa |
| Incyte Corporation | $118.16 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $116.24 | 2019-2025 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $113.91 | 2019-2024 | Libtayo |
| Abbvie INC. | $102.26 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $87.24 | 2019-2021 | |
| Mirati Therapeutics, INC. | $77.27 | 2023-2024 | Krazati |
| Eisai INC. | $70.59 | 2019-2022 | |
| Pfizer INC. | $70.14 | 2021-2025 | |
| Accord Healthcare, INC. | $65.43 | 2024-2025 | |
| Kite Pharma, INC. | $63.17 | 2020-2021 | |
| Tactile Systems Technology INC | $57.97 | 2024 | Flexitouch Plus, Entre Plus |
| Tersera Therapeutics LLC | $48.32 | 2023-2025 | Xermelo, Zoladex |
| Myovant Sciences INC. | $46.50 | 2021-2022 | |
| Adc Therapeutics America, INC. | $43.61 | 2024-2025 | |
| Geron Corporation | $41.94 | 2025 | Rytelo |
| Acceleron Pharma, INC. | $40.17 | 2021 | |
| Servier Pharmaceuticals LLC | $38.33 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $38.13 | 2024-2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $34.99 | 2024 | Ogsiveo |
| Gilead Sciences, INC. | $34.82 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $29.46 | 2022-2025 | Monoferric |
| Tempus Ai, INC | $28.03 | 2025 | Xt Cdx |
| Sobi, INC | $27.87 | 2024 | |
| Genentech USA, INC. | $25.08 | 2021 | |
| Caris Mpi, INC. | $24.22 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $22.89 | 2021 | |
| Emd Serono, INC. | $21.13 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.87 | 2021 | |
| Myriad Genetic Laboratories, INC. | $19.54 | 2022 | |
| Astellas Pharma US INC | $18.46 | 2022 | |
| Blueprint Medicines Corporation | $16.28 | 2025 | Ayvakit |
| Stemline Therapeutics INC. | $15.61 | 2025 | Orserdu |
| Novocure INC. | $15.60 | 2025 | Optune Lua (Novottf-200t) |
| Alnylam Pharmaceuticals INC. | $13.75 | 2024 | Oxlumo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahakit Inklab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.